A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioma
- Focus Therapeutic Use
Most Recent Events
- 08 Jan 2025 Status changed from active, no longer recruiting to discontinued.
- 28 Nov 2024 Planned End Date changed from 1 Dec 2025 to 1 May 2025.
- 28 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 May 2025.